Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.